Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) closed the day trading at $9.95 down -11.24% from the previous closing price of $11.21. In other words, the price has decreased by -$11.24 from its previous closing price. On the day, 0.77 million shares were traded. YMAB stock price reached its highest trading level at $10.48 during the session, while it also had its lowest trading level at $8.41.
Ratios:
For a better understanding of YMAB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $21.
On May 10, 2023, Wedbush Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $5 to $13.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 11 ’24 when Gad Thomas sold 35,000 shares for $12.00 per share. The transaction valued at 420,000 led to the insider holds 162,681 shares of the business.
Gad Thomas sold 35,000 shares of YMAB for $421,050 on Jun 10 ’24. The CHIEF BUSINESS OFFICER now owns 197,681 shares after completing the transaction at $12.03 per share. On Jun 10 ’24, another insider, Ber Gerard, who serves as the Director of the company, sold 722 shares for $12.00 each. As a result, the insider received 8,664 and left with 1,608 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 491924000 and an Enterprise Value of 362064256. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.17 while its Price-to-Book (P/B) ratio in mrq is 4.65. Its current Enterprise Value per Revenue stands at 4.285 whereas that against EBITDA is -14.859.
Stock Price History:
Over the past 52 weeks, YMAB has reached a high of $20.90, while it has fallen to a 52-week low of $4.60. The 50-Day Moving Average of the stock is -16.68%, while the 200-Day Moving Average is calculated to be -13.33%.
Shares Statistics:
Over the past 3-months, YMAB traded about 288.70K shares per day on average, while over the past 10 days, YMAB traded about 235380 shares per day. A total of 43.67M shares are outstanding, with a floating share count of 36.23M. Insiders hold about 17.44% of the company’s shares, while institutions hold 53.93% stake in the company. Shares short for YMAB as of 1721001600 were 4236564 with a Short Ratio of 16.14, compared to 1718323200 on 3655283. Therefore, it implies a Short% of Shares Outstanding of 4236564 and a Short% of Float of 11.63.
Earnings Estimates
Y-Mabs Therapeutics Inc (YMAB) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.08 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.35 and -$0.81 for the fiscal current year, implying an average EPS of -$0.53. EPS for the following year is -$0.58, with 7.0 analysts recommending between -$0.15 and -$0.97.
Revenue Estimates
6 analysts predict $23.02M in revenue for the current quarter. It ranges from a high estimate of $24.39M to a low estimate of $22M. As of the current estimate, Y-Mabs Therapeutics Inc’s year-ago sales were $20.75MFor the next quarter, 6 analysts are estimating revenue of $25.24M. There is a high estimate of $26.8M for the next quarter, whereas the lowest estimate is $24.31M.
A total of 8 analysts have provided revenue estimates for YMAB’s current fiscal year. The highest revenue estimate was $100.1M, while the lowest revenue estimate was $89M, resulting in an average revenue estimate of $95.18M. In the same quarter a year ago, actual revenue was $84.82MBased on 8 analysts’ estimates, the company’s revenue will be $115.6M in the next fiscal year. The high estimate is $133M and the low estimate is $104.72M.
